Follow the 티움바이오 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 티움바이오 has recorded 24 insider filings. Market capitalisation: €120.3bn. The latest transaction was filed on 24 June 2026 (Other). Among the most active insiders: 김훈택. Every trade is accessible without an account.
24
Insider Decl.
n/a
Thresholds
n/a
6 ops.
Buy Volume
n/a
5 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,617 of 28,124 companies
24.4
score / 100
Value
15
Quality
34
FCF yld-11%
Earn yld-13%
EV/EBITDA·
ROE-32%
Gross mgn41%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
티움바이오 is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative therapies and biopharmaceutical solutions.